Fragment-based binding effciency indices in bioactive molecular design: A computational approach to BACE-1 inhibitors

Iranian Journal of Pharmaceutical Research

Volumn 12, Issue 3, 2013, Pages 423-436

  Razzaghi Asl, Nima ^a,b   Ebadi, Ahmad ^a,b   Edraki, Najmeh ^a   Shahabipour, Sara ^a   Miri, Ramin ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Alzheimer; BACE 1; Docking; Ligand efficiency

Indexed keywords

BETA SECRETASE 1; BETA SECRETASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; DRUG SCREENING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; IC 50; LIGAND BINDING; MOLECULAR DOCKING; SIMULATION; X RAY CRYSTALLOGRAPHY;

EID: 84883758803     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Querfurth HW LF. Alzheimer's disease. N. Engl. J. Med. (2010) 362: 329-44.
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR and Zalutsky R. How common are the "common" neurologic disorders? Neurology. (2007) 68: 326-37.
3. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. (2009) 110: 1129-34.
4. Pietrzik C and Behl C. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. (2005) 86: 173-85.
5. Selkoe DJ. Soluble oligomers of the amyloid (beta)-protein impair synaptic plasticity and behavior. Behav. Brain Res. (2008) 192: 106-13.
6. Albert JS. 4 Progress in the Development of (beta)-secretase Inhibitors for Alzheimer's Disease. Progr. Med. Chem. (2009) 48: 133-61.
7. Ziora Z, Kimura T and Kiso Y. Small-sized BACE1 inhibitors. Drugs Future. (2006) 31: 53-63.
8. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. (2000) 44: 235-49.
9. Lipinski CA, Lombardo F, Dominy BW and Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliver. Rev. (1997) 23: 3-25.
10. Lipinski CA. Lead-and drug-like compounds: the rule-of-fve revolution. Drug Discov. Today Technol. (2004) 1: 337-41.
11. Muegge I. Selection criteria for drug-like compounds. Med. Res. Rev. (2003) 23: 302-21.
12. Andrews PR, Craik DJ and Martin JL. Functional group contributions to drug-receptor interactions. J. Med. Chem. (1984) 27: 1648-57.
13. Abad-Zapatero C and Metz JT. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today (2005) 10: 464-69.
14. Tanaka D TY, Shiyama T, Nishimura T, Chiyo N, Tominaga Y, Sawada N, Mimoto T, Kusunose N. A Practical Use of Ligand Effciency Indices Out of the Fragment-Based Approach: Ligand Effciency-Guided Lead Identifcation of Soluble Epoxide Hydrolase Inhibitors. J. Med. Chem. (2011) 54: 851-57.
15. Reynolds CH TB and Bembenek SD. Ligand binding effciency: Trends, Physical Basis, and Implications. J. Med. Chem. (2008) 51: 2432-38.
16. Hetényi C, Paragi G, Maran U, Timár Z, Karelson M and Penke B. Combination of a modifed scoring function with twodimensional descriptors for calculation of binding affnities of bulky, fexible ligands to proteins. J. Am. Chem. Soc. (2006) 128: 1233-39.
17. Hetényi C, Maran U, Garci ́a-Sosa AT and Karelson M. Structure-based calculation of drug effciency indices. Bioinformatics (2007) 23: 2678-85.
18. McGovern SL and Shoichet BK. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem.(2003) 46: 2895-907.
19. Chang MW, Ayeni C, Breuer S and Torbett BE. Virtual Screening for HIV Protease Inhibitors: A Comparison of AutoDock 4 and Vina. PLoS ONE. (2010) 5: e11955.
20. Todeschini R Milano Chemometrics and QSAR Group, http://www.disat.unimib.it/vhm/
21. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS and Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor fexibility. J. Comput. Chem. (2009) 30: 2785-91.
22. Vriend G HR and van Aalten T. WHAT IF manual. Heidelberg Germany: European Molecular Biology Laboratory. (1997).
23. Baxevanis AD. Current protocols in bioinformatics. John Wiley & Sons, Inc. (2002) 6.
24. Wallace AC, Laskowski RA and Thornton JM. Ligplot-a program to generate schematic diagrams of protein ligand interactions. Protein Eng. (1995) 8: 127-34.
25. Bemis GW and Murcko MA. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. (1996) 39: 2887-93.
26. Hansen PJ and Jurs PC. Chemical applications of graph theory. Part I. Fundamentals and topological indices. J. Chem. Educ. (1988) 65: 574-79.
27. Hopkins AL, Groom CR and Alex A. Ligand effciency: a useful metric for lead selection. Drug Discov. Today (2004) 9: 430-31.
28. Orita M, Ohno K and Niimi T. Two () Golden Ratio'indices in fragment-based drug discovery. Drug Discov. Today (2009) 14: 321-28.
29. Wenlock MC, Austin RP, Barton P, Davis AM and Leeson PD. A comparison of physiochemical property profles of development and marketed oral drugs. J. Med. Chem. (2003) 46: 1250-56.
30. Razzaghi-Asl N, Ebadi A, Edraki N, Mehdipour A, Shahabipour S and Mir R. Response surface methodology in docking study of small molecule BACE-1 inhibitor. J. Mol. Mod. (2012).
31. Patel S, Vuillard L, Cleasby A, Murray CW and Yon J. Apo and Inhibitor Complex Structures of BACE ((beta)-secretase). J. Mol. Biol. (2004) 343: 407-16.
32. Zhu Z, Sun ZY, Ye Y, Voigt J, Strickland C, Smith EM, Cumming J, Wang L, Wong J and Wang YS. Discovery of cyclic acylguanidines as highly potent and selective -site amyloid cleaving enzyme (BACE) inhibitors: part i inhibitor design and validation (1). J. Med. Chem. (2010) 53: 951-965.
33. Kortum SW, Benson TE, Bienkowski MJ, Emmons TL, Prince DB, Paddock DJ, Tomasselli AG, Moon JB, LaBorde A and TenBrink RE. Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1. Bioorg. Med. Chem. Lett. (2007) 17: 3378-83.